OrbiMed is a healthcare investment firm that provides tailored financing solutions and global team resources to help build world-class healthcare companies.

OrbiMed

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Zai Lab

LogicBio Therapeutics

Magenta Therapeutics

BiolineRx

Century Therapeutics

Constellation Pharmaceuticals

Crinetics Pharmaceuticals

Cullinan Oncology

Erasca

Natera

Nautilus Biotechnology

Netmeds

NeuroPace

ORIC Pharmaceuticals

Owlet Baby Care

Terns Pharmaceuticals

Third Harmonic Bio

TigerConnect

Tricida

Valneva

VectivBio

Gelesis

Graphite Bio

Guardant Health

Health Catalyst

Imara

Insmed

Inspire Medical Systems

Intellia Therapeutics

Sierra Oncology

Puma Biotechnology

RedHill Biopharma

ReViral

scPharmaceuticals

Sientra

Syndax Pharmaceuticals

AbCellera

Acutus Medical

Invivyd

Adaptive Biotechnologies

Affimed

Alector

Alpine Immune Sciences

Amolyt Pharma

Arcutis Biotherapeutics

Ascendis Pharma

Athersys

Ventyx Biosciences

ViewRay

Augmedix

Sonendo

Invitae

Kala Pharmaceuticals

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Google Analytics

DNSSEC

WordPress

Global Site Tag

Chief Risk Officer

Andrew Kanarek

Legal

Clark Chu

Chief Technology Officer

Daniel Rhee

Chief Compliance Officer

Douglas Coon

Evan Sotiriou

Chief Financial Officer

Trey Block

Vice President

Brendan Weber

Vice President, Data Engineer

Corey Schrader

Evan Caplan

Private Equity Vice President

Kipyegon Kitur

Jason Glover

Derivatives Trader

Doug Coon

Jonathan Silverstein

Co-Head of Private Equity and Managing Partner

David Wang

Partner & Senior Managing Director, Asia

Nissim Darvish

Venture Partner

Joseph Kleeman

Senior Trader

Anat Naschitz

Peter Thompson

Private Equity Partner

XtalPi is a pharmaceutical technology company that is reinventing drug discovery by enabling dry lab predictions with wet lab validation.

Humacyte develops products for vascular diseases and replacement of anatomical conduits.

TigerConnect is a healthcare collaboration platform that streamlines clinical workflows and systems.

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.

enGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins.

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.

Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global disease burden. 

Private Equity Stage Investors with Investments in England

Debt Investors with Investments in East Coast

Private Equity Firms with Investments in California

Private Equity Stage Investors with Investments in London, England

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed Royalty & Credit Opportunities IV

OrbiMed Asia Partners V

OrbiMed Private Investments IX

OrbiMed Private Investments VIII

OrbiMed Royalty & Credit Opportunities III

OrbiMed Asia Partners IV

Private Investments VII

OrbiMed Asia Partners III

OrbiMed Israel Partners II

OrbiMed Private Investments VI, LP

New York

United States

North America

Texas County & District picks OrbiMed, Linden Capital for latest alts commitments

Dallas’ Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors

Alentis Therapeutics–Bellevue: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor BB Pureos

Alentis Therapeutics–Frazier: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Frazier Life Sciences

Alentis Therapeutics–Jeito Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Jeito Capital

Alentis Therapeutics–France (govt): investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Bpifrance InnoBio 2 Fund

Alentis Therapeutics–Piper Heartland Healthcare Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor PHHC

Alentis Therapeutics–RA Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor RA Capital Management

Italy

Europe

Russian Federation

United Kingdom

Philippines

Asia

HTML5

AmplifyJS

.NET 4.5

Microsoft Outlook

jQuery

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 11, 2024 4:08 PM	3b38232e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	f6949c43
crunchbase profile	general	Nov 25, 2024 11:35 AM	72166142
li profile	general	Jul 11, 2024 4:08 PM	8c52439d
translate crunchbase fundingrounds	general	Nov 25, 2024 2:17 PM	c6a9e990
peers	general	Jul 11, 2024 4:08 PM	6407b8ae
news basic	general	Jul 11, 2024 4:08 PM	9ab33708
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ORBI

COM:ORBIMED

OrbiMed